Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 the Company’s ability to continue as a going concern.

The unaudited condensed consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might result from the outcome of this uncertainty.

NOTE 3 – SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES

Basis
of Presentation

The accompanying financial statements are presented
in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US
GAAP”), and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).
The unaudited condensed consolidated financial statements include the accounts of INmune Bio Inc. and its subsidiaries. Intercompany transactions
and balances have been eliminated.

In the opinion
of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results
for the interim periods. These unaudited condensed consolidated interim financial statements should be read in conjunction with
the audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.

6

Risks and Uncertainties

The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to
obtain additional financing to fund operations. Product candidates currently under development will require significant additional research
and development efforts, including extensive preclinical studies, clinical trials and regulatory approval prior to commercialization.
These efforts require significant amounts of additional resources, adequate personnel, infrastructure and extensive compliance and reporting.

The Company’s product candidates are still
in development and, to date, none of the Company’s product candidates have been approved for sale.

There can be no assurance that the Company’s
research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be
obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products
will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the
Company will generate any revenue from any of its products.